Bexson Biomedical, Inc. is developing a subcutaneous ketamine treatment platform for non-opioid, outpatient pain management. It is collaborating with Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery system. The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106. The two companies will work closely together to produce a small, wearable, and programmable device, leveraging Stevanato Group’s experience in contract manufacturing and medical device innovation. This technology will pair with Bexson’s ketamine therapy to provide consumers with non-opioid treatment for chronic and acute pain types.
The SG EZ-be Pod® is a discreet on-body wearable device which will be ideally suited to the needs of consumers receiving pain management treatment. Stevanato Group’s device is designed to enable dynamic and convenient subcutaneous delivery for consumers, compared to current ketamine infusions that have a high procedural burden and high cost. Bexson’s proprietary formulation, BB106, will allow for steady-state plasma levels, which are currently only achieved by intravenous delivery in clinic or hospital settings.
Bexson Biomedical, Inc. is a research stage company developing a ketamine-based combination product treatment platform for a wide variety of pain management and mental health disorders. The company’s lead indication for its BB106 therapy is post-operative pain.
Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process.
This was reported by Bexson Biomedical on September 21, 2020.
Contact information: Bexson Biomedical, Inc., 369 Paso Robles Dr,, Santa Barbara, CA 93108; Website: https://www.bexsonbiomedical.com.
